Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Johnson

Showing results (131-140 of 152) with videos related to

Pageof 16
Sort By:
Nature Communications|July 26, 2020
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer modelsHyoung Kim, Haineng Xu, Erin George, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|February 10, 2016
Preclinical Experimental and Mathematical Approaches for Assessing Effective Doses of Inhaled Drugs, Using Mometasone to Support Human Dose PredictionsMichael Caniga, Antonio Cabal, Khamir Mehta, et al.
Cell Reports|September 27, 2018
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor ResistanceJoseph Nacson, John J Krais, Andrea J Bernhardy, et al.
Cell Reports|November 1, 2018
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor ResistanceJoseph Nacson, John J Krais, Andrea J Bernhardy, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceNeil Johnson, Shawn F Johnson, Wei Yao, et al.
Journal of Medicinal Chemistry|October 22, 2025
RTx-303, an Orally Bioavailable Polθ Polymerase Inhibitor That Potentiates PARP Inhibitors in BRCA Mutant TumorsGurushankar Chandramouly, William Fried, John Gordon, et al.
Nature Communications|November 24, 2023
Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilitiesJohn J Krais, David J Glass, Ilse Chudoba, et al.
Cell Reports|June 14, 2018
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor CellsKatherine Sullivan-Reed, Elisabeth Bolton-Gillespie, Yashodhara Dasgupta, et al.
Nature Communications|April 5, 2024
Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitorsWilliam Fried, Mrityunjay Tyagi, Leonid Minakhin, et al.
JCI Insight|January 19, 2017
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancersErin George, Hyoung Kim, Clemens Krepler, et al.
Pageof 16

Showing results (131-140 of 152) with videos related to

Sort By:
Pageof 16
Nature Communications|July 26, 2020
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer modelsHyoung Kim, Haineng Xu, Erin George, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|February 10, 2016
Preclinical Experimental and Mathematical Approaches for Assessing Effective Doses of Inhaled Drugs, Using Mometasone to Support Human Dose PredictionsMichael Caniga, Antonio Cabal, Khamir Mehta, et al.
Cell Reports|September 27, 2018
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor ResistanceJoseph Nacson, John J Krais, Andrea J Bernhardy, et al.
Cell Reports|November 1, 2018
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor ResistanceJoseph Nacson, John J Krais, Andrea J Bernhardy, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceNeil Johnson, Shawn F Johnson, Wei Yao, et al.
Journal of Medicinal Chemistry|October 22, 2025
RTx-303, an Orally Bioavailable Polθ Polymerase Inhibitor That Potentiates PARP Inhibitors in BRCA Mutant TumorsGurushankar Chandramouly, William Fried, John Gordon, et al.
Nature Communications|November 24, 2023
Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilitiesJohn J Krais, David J Glass, Ilse Chudoba, et al.
Cell Reports|June 14, 2018
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor CellsKatherine Sullivan-Reed, Elisabeth Bolton-Gillespie, Yashodhara Dasgupta, et al.
Nature Communications|April 5, 2024
Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitorsWilliam Fried, Mrityunjay Tyagi, Leonid Minakhin, et al.
JCI Insight|January 19, 2017
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancersErin George, Hyoung Kim, Clemens Krepler, et al.
Pageof 16